• Alexandra Sachkova, Eya Khadhraoui, Sergey Goryaynov, Artem Batalov, Kristina D Solozhentseva, Igor Pronin, Dorothee Mielke, Veit Rohde, and Tammam Abboud.
• Department of Anesthesiology, University Medical Center Göttingen, Göttingen, Germany; Department of Neurosurgery, University Medical Center Göttingen, Göttingen, Germany.
• World Neurosurg. 2023 Feb 1; 170: e159e169e159-e169.

BackgroundMeningeosis neoplastica is a rare manifestation of high-grade gliomas and is usually associated with a devastating outcome. The aim of this bicenter series was to investigate the clinical course and outcome of patients with meningiosis neoplastica.MethodsThis case series included patients in whom surgery was performed for World Health Organization grade IV primary and secondary glioblastoma (GBM) at the University Medical Center Göttingen, Göttingen, Germany between 2009 and 2021 and Burdenko Institute of Neurosurgery, Moscow, Russia between 2012 and 2018. Inclusion criteria were manifestation of clinical and neuroradiologic signs of leptomeningeal, ependymal, or spinal dissemination of GBM at various time points during the course of the disease.ResultsMeningeosis neoplastica was found in 36 patients. Nine patients developed spinal metastases and 12 ependymal dissemination and 15 patients had a leptomeningeal manifestation of high-grade glioma. The median age of patients at first diagnosis of primary tumor was 56 years. Typical symptoms were headache, nausea, vomiting, and acute paraplegia. The median overall survival was 11 months and progression-free survival was 8 months. Meningeosis neoplastica developed a median 2 months after the initial tumor diagnosis. Salvage therapies included ventriculoperitoneal shunting, decompression of spinal metastases, and spinal radiation therapy. The median time between meningeosis manifestation and death was 3 months.ConclusionsMeningeosis neoplastica is a rare manifestation of GBM. It has a poor prognosis. The overall survival after the manifestation of meningeosis was barely longer than 3 months. Salvage therapies did not improve the outcome in our patient cohort.Copyright © 2022 Elsevier Inc. All rights reserved.

18 keywords...

hide…